KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 31, 2025
-- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) --
-- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 --
Read more at globenewswire.comNASDAQ:KALA (8/22/2025, 3:23:51 PM)
9.0236
+0.52 (+6.16%)
Find more stocks in the Stock Screener
